Condition
Crohn's Disease
Clear, practical articles to help you understand Crohn's Disease symptoms, medications, flares, nutrition, and everyday disease management. Browse our articles below.
Omvoh vs Remicade for Crohn's Disease: Which to Choose?
Omvoh and Remicade represent two very different generations of Crohn's biologic therapy. Remicade has been the anti-TNF standard for Crohn's since the late 1990s. Omvoh is the newest IL-23 p19-selective biologic for Crohn's, gaining FDA approval in January 2025 based on the VIVID-1 trial. Patients commonly compare these drugs when choosing a first-line biologic or when weighing alternatives after Remicade has lost effect. This guide walks through the omvoh vs remicade crohn's comparison.
Omvoh vs Humira for Crohn's Disease: A Comparison
Omvoh and Humira are two biologics for moderate-to-severe Crohn's disease that work through very different mechanisms. Humira is a fully human anti-TNF biologic with more than two decades of experience in IBD. Omvoh is an IL-23 p19-selective biologic approved for Crohn's in January 2025 based on the VIVID-1 trial. Patients weighing these two drugs are often choosing between an established anti-TNF and a newer IL-23 option. This guide walks through the omvoh vs humira crohn's decision.
Omvoh vs Entyvio for Crohn's Disease: A Comparison
Omvoh and Entyvio are two non-anti-TNF biologics for moderate-to-severe Crohn's disease, each offering meaningful safety advantages over anti-TNFs through very different mechanisms. Omvoh is an IL-23 p19-selective biologic approved for Crohn's in January 2025 based on VIVID-1. Entyvio is gut-selective and has been a Crohn's treatment option since 2014. Patients comparing these drugs often prioritize long-term safety or are weighing alternatives after anti-TNF failure. This guide walks through the omvoh vs entyvio crohn's decision.
Entyvio vs Stelara for Crohn's Disease: Which Is Better?
Entyvio and Stelara are two of the most common biologics prescribed when an anti-TNF like Humira or Remicade stops working for Crohn's disease. Both are alternatives to TNF blockade, but they take very different mechanistic paths to quiet gut inflammation. Entyvio is gut-selective. Stelara targets a cytokine pathway that operates throughout the body but is especially active in the gut. For patients weighing a second-line choice, the decision often hinges on infection risk, onset of action, and long-term safety. This guide walks through the evidence patients need to make an informed entyvio vs stelara crohn's decision with their gastroenterologist.
Cimzia vs Tremfya for Crohn's Disease: A Patient Guide
Cimzia and Tremfya represent two very different generations of biologic therapy for moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic that has been a Crohn's option since 2008. Tremfya (guselkumab) is an IL-23 p19-selective biologic that gained Crohn's approval in March 2025 based on GALAXI-2, GALAXI-3, and GRAVITI. Patients comparing these drugs weigh established anti-TNF mechanism against a newer IL-23 class with distinctive induction flexibility. This guide walks through the cimzia vs tremfya crohn's comparison.
Cimzia vs Stelara for Crohn's Disease: How They Compare
Cimzia and Stelara are two subcutaneous biologics for moderate-to-severe Crohn's disease that work through fundamentally different mechanisms. Cimzia (certolizumab pegol) is an anti-TNF biologic. Stelara (ustekinumab) is an IL-12/23 inhibitor. Patients comparing these drugs often weigh established TNF-alpha blockade against the IL-12/23 pathway, particularly when considering first-line therapy or switching after anti-TNF failure. This guide walks through the cimzia vs stelara crohn's decision.
Cimzia vs Skyrizi for Crohn's Disease: Comparing Options
Cimzia and Skyrizi represent two different generations of biologic therapy for moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic that has been a Crohn's option since 2008. Skyrizi (risankizumab) is an IL-23 p19-selective biologic approved for Crohn's in June 2022 based on the ADVANCE, MOTIVATE, and FORTIFY trials. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with strong efficacy and safety data. This guide walks through the cimzia vs skyrizi crohn's comparison.
Cimzia vs Remicade for Crohn's Disease: Key Differences
Cimzia and Remicade are two anti-TNF biologics for moderate-to-severe Crohn's disease, but they take different administration routes. Cimzia (certolizumab pegol) is a subcutaneous injection. Remicade (infliximab) is an intravenous infusion. Both block TNF-alpha, but the administration difference and Cimzia's unique Fab structure shape the practical comparison. This guide walks through the cimzia vs remicade crohn's decision.
Cimzia vs Omvoh for Crohn's Disease: Which Is Better?
Cimzia and Omvoh represent two very different generations of biologic therapy for moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic that has been a Crohn's option since 2008. Omvoh (mirikizumab) is a newer IL-23 p19-selective biologic that gained Crohn's approval in January 2025 based on VIVID-1. Patients comparing these drugs weigh established anti-TNF mechanism against a newer IL-23 class. This guide walks through the cimzia vs omvoh crohn's comparison.
Cimzia vs Humira for Crohn's Disease: Comparing Anti-TNFs
Cimzia and Humira are two subcutaneous anti-TNF biologics for moderate-to-severe Crohn's disease. Both block TNF-alpha, but they differ in molecular structure in ways that can matter for specific patient populations, particularly those considering pregnancy. Cimzia (certolizumab pegol) is a PEGylated antibody fragment without an Fc region, while Humira (adalimumab) is a full IgG antibody. This guide walks through the cimzia vs humira crohn's comparison.
Cimzia vs Entyvio for Crohn's Disease: A Comparison
Cimzia and Entyvio take very different mechanistic approaches to moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic. Entyvio (vedolizumab) is a gut-selective biologic. Patients comparing these drugs often weigh a systemic anti-TNF approach against a gut-targeted strategy with a favorable systemic safety profile. This guide walks through the cimzia vs entyvio crohn's comparison.
Stelara vs Remicade for Crohn's Disease: Comparing Biologics
Stelara vs Remicade for Crohn's: mechanism, healing, safety, and dosing compared.